← Back to Search

Low-Flow vs. High-Flow Nasal Cannula for Hypoxia in Immunocompromised Patients

Q: Is recruitment still open for this experiment?

<p>Clinicaltrials.gov's records depict that this investigation has ceased seeking out participants, having been posted in the 10th of January 2018 and updated on April 4th 2022. Nevertheless, there are 2,697 other medical studies currently recruiting patients.</p>

N/A

Waitlist Available

Led By Dr. Sangeeta Mehta, MD, FRCPC

Research Sponsored by Mount Sinai Hospital, Canada

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up the spo2 will be measured using a bedside spo2 measuring device during or 1 hour post-fob defined as a drop in spo2 of 4% or more for > 1 minute or any drop in o2 <90% necessitating an increase in fio2 to maintain a saturation ≥92% for at least 1 minute.

Awards & highlights

Study Summary

This trial tests whether using Optiflow during bronchoscopy prevents drops in blood oxygen levels.

Who is the study for?

This trial is for adults over 18 who are immunocompromised due to blood cancers or bone marrow transplant, need extra oxygen to keep their blood levels normal, and are scheduled for a lung infection test called FOB. It's not for those with high carbon dioxide levels in their blood, severe acidosis, already using high-flow oxygen, needing very high oxygen before the study starts, or with nasal issues that prevent using the devices.Check my eligibility

What is being tested?

The trial tests two ways of giving extra oxygen during a lung infection test (FOB): one uses low flow through the nose (usual method), and the other uses 'Optiflow' which gives higher flow comfortably. The goal is to see if Optiflow can better prevent drops in blood oxygen levels during the procedure.See study design

What are the potential side effects?

Potential side effects may include discomfort from wearing nasal cannulas and dryness or irritation inside the nose from airflow. High-flow systems might also cause more dryness or pressure-related discomfort compared to low-flow.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ the spo2 will be measured using a bedside spo2 measuring device during or 1 hour post-fob defined as a drop in spo2 of 4% or more for > 1 minute or any drop in o2 <90% necessitating an increase in fio2 to maintain a saturation ≥92% for at least 1 minute.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~the spo2 will be measured using a bedside spo2 measuring device during or 1 hour post-fob defined as a drop in spo2 of 4% or more for > 1 minute or any drop in o2 <90% necessitating an increase in fio2 to maintain a saturation ≥92% for at least 1 minute.

This trial's timeline: 3 weeks for screening, Varies for treatment, and the spo2 will be measured using a bedside spo2 measuring device during or 1 hour post-fob defined as a drop in spo2 of 4% or more for > 1 minute or any drop in o2 <90% necessitating an increase in fio2 to maintain a saturation ≥92% for at least 1 minute. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Desaturation during FOB

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: High Flow Nasal Cannula (HFNC)Experimental Treatment1 Intervention

Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.

Group II: Low Flow Nasal Cannula (LFNC)Active Control1 Intervention

Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mount Sinai Hospital, CanadaLead Sponsor

196 Previous Clinical Trials

67,510 Total Patients Enrolled

Princess Margaret Hospital, CanadaOTHER

119 Previous Clinical Trials

38,961 Total Patients Enrolled

Dr. Sangeeta Mehta, MD, FRCPCPrincipal InvestigatorMOUNT SINAI HOSPITAL

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment still open for this experiment?

"Clinicaltrials.gov's records depict that this investigation has ceased seeking out participants, having been posted in the 10th of January 2018 and updated on April 4th 2022. Nevertheless, there are 2,697 other medical studies currently recruiting patients."

Answered by AI

Recent research and studies

Critical Care Research and PracticeJournal

High-flow Nasal Interface Improves Oxygenation in Patients Undergoing Bronchoscopy

Lucangelo, Umberto, Fabio Giuseppe Vassallo, Emanuele Marras, Massimo Ferluga, Elena Beziza, Lucia Comuzzi, Giorgio Berlot, and Walter Araujo Zin. 2012. “High-flow Nasal Interface Improves Oxygenation in Patients Undergoing Bronchoscopy”. Critical Care Research and Practice. Hindawi Limited. doi:10.1155/2012/506382.

Critical Care MedicineJournal

Use of High-flow Nasal Cannula Oxygen Therapy to Prevent Desaturation During Tracheal Intubation of Intensive Care Patients with Mild-to-moderate Hypoxemia*

Miguel-Montanes, Romain, David Hajage, Jonathan Messika, Fabrice Bertrand, Stéphane Gaudry, Cédric Rafat, Vincent Labbé, et al.. 2015. “Use of High-flow Nasal Cannula Oxygen Therapy to Prevent Desaturation During Tracheal Intubation of Intensive Care Patients with Mild-to-moderate Hypoxemia*”. Critical Care Medicine. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/ccm.0000000000000743.

European Respiratory JournalJournal

Increased Use of High-flow Nasal Oxygen During Bronchoscopy

La Combe, Beatrice, Jonathan Messika, Muriel Fartoukh, and Jean-Damien Ricard. 2016. “Increased Use of High-flow Nasal Oxygen During Bronchoscopy”. European Respiratory Journal. European Respiratory Society (ERS). doi:10.1183/13993003.00565-2016.

British Journal of AnaesthesiaJournal